Browsing by Author "Wasilewski, Piotr (57519434500)"
Now showing 1 - 1 of 1
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug–drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19)(2022) ;Lakatos, Botond (36614563800) ;Kowalska, Justyna (35105197800) ;Antoniak, Sergii (57196322148) ;Gokengin, Deniz (6603234930) ;Begovac, Josip (7004168039) ;Vassilenko, Anna (57223414705) ;Wasilewski, Piotr (57519434500) ;Fleischhans, Lukas (57205362262) ;Jilich, David (22234091800) ;Matulionyte, Raimonda (12239067500) ;Kase, Kerstin (57216676281) ;Papadopoulus, Antonios (57360635200) ;Rukhadze, Nino (54883291900) ;Harxhi, Arjan (8690048500) ;Hofman, Sam (57360783400) ;Dragovic, Gordana (23396934400) ;Vasyliev, Marta (57360924200) ;Verhaz, Antonija (6507063101) ;Yancheva, Nina (36910505000)Oprea, Cristiana (21636591500)Objectives: The aim of this international multicentre study was to review potential drug–drug interactions (DDIs) for real-life coadministration of combination antiretroviral therapy (cART) and coronavirus disease 2019 (COVID-19)-specific medications. Methods: The Euroguidelines in Central and Eastern Europe Network Group initiated a retrospective, observational cohort study of HIV-positive patients diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Data were collected through a standardized questionnaire and DDIs were identified using the University of Liverpool's interaction checker. Results: In total, 524 (94.1% of 557) patients received cART at COVID-19 onset: 117 (22.3%) were female, and the median age was 42 (interquartile range 36–50) years. Only 115 (21.9%) patients were hospitalized, of whom 34 required oxygen therapy. The most frequent nucleoside reverse transcriptase inhibitor (NRTI) backbone was tenofovir disoproxil fumarate (TDF)/tenofovir alafenamide (TAF) with lamivudine or emtricitabine (XTC) (79.3%) along with an integrase strand transfer inhibitor (INSTI) (68.5%), nonnucleoside reverse transcriptase inhibitor (NNRTI) (17.7%), protease inhibitor (PI) (13.7%) or other (2.5%). In total, 148 (28.2%) patients received COVID-19-specific treatments: corticosteroids (15.7%), favipiravir (7.1%), remdesivir (3.1%), hydroxychloroquine (2.7%), tocilizumab (0.6%) and anakinra (0.2%). In total, 62 DDI episodes were identified in 58 patients (11.8% of the total cohort and 41.9% of the COVID-19-specific treatment group). The use of boosted PIs and elvitegravir accounted for 43 DDIs (29%), whereas NNRTIs were responsible for 14 DDIs (9.5%). Conclusions: In this analysis from the Central and Eastern European region on HIV-positive persons receiving COVID-19-specific treatment, it was found that potential DDIs were common. Although low-dose steroids are mainly used for COVID-19 treatment, comedication with boosted antiretrovirals seems to have the most frequent potential for DDIs. In addition, attention should be paid to NNRTI coadministration. © 2021 British HIV Association.
